reports
- Maxime Dubreil
Abivax to be Added to Nasdaq Biotechnology Index
Abivax to be Added to Nasdaq Biotechnology Index Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025. Didie...
CARBIOS maintains its commitment to build the Longlaville plant and ad...
CARBIOS maintains its commitment to build the Longlaville plant and adjusts its timeline CARBIOS reaffirms its ambition to pursue the Longlaville plant construction project and postpones the timeline by three-month.The plant construction project is supported by: Pre-commercialization contracts covering close to 50% of the production capacity of the future industrial site in Longlaville.Significant progress in structuring the additional financing required to restart the project.Secured public funding of €42.5 million. A small portion1 of the financing still needs to be secured before the p...
CARBIOS maintient son objectif de construction de l’usine de Longlavil...
CARBIOS maintient son objectif de construction de l’usine de Longlaville avec un calendrier ajusté CARBIOS réaffirme son ambition de poursuivre le projet de construction de l’usine à Longlaville en décalant le calendrier prévisionnel de trois mois.Le projet de construction de l’usine est aujourd’hui conforté par : Des contrats de pré-commercialisation couvrant près de 50 % de la capacité de production du futur site industriel de Longlaville.Des avancées significatives dans la structuration des financements complémentaires nécessaires au redémarrage du projet.Des aides publiques confirmées à...
- Patrick Steiner
APAML APERAM SA
ACN ACCENTURE PLC CLASS A
EXE EXEL INDUSTRIES SA
INF INFOTEL SA
EVN EVN AG
SWP SWORD GROUP SE
AUB AUBAY SA
ATE ALTEN SA
COTN COMET HOLDING AG
CAP CAPGEMINI SE
TXGN TX GROUP AG
DEZ DEUTZ AG
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
CIE CIE AUTOMOTIVE S.A.
LFDE LA FRANCAISE DE L'ENERGIE SA
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
NA9 NAGARRO
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
IFCN INFICON HOLDING AG
- Patrick Steiner
APAML APERAM SA
ACN ACCENTURE PLC CLASS A
EXE EXEL INDUSTRIES SA
INF INFOTEL SA
EVN EVN AG
SWP SWORD GROUP SE
AUB AUBAY SA
ATE ALTEN SA
COTN COMET HOLDING AG
CAP CAPGEMINI SE
TXGN TX GROUP AG
DEZ DEUTZ AG
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
CIE CIE AUTOMOTIVE S.A.
LFDE LA FRANCAISE DE L'ENERGIE SA
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
NA9 NAGARRO
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
IFCN INFICON HOLDING AG
- Ghada Ben Sedrine
- Nicolas David
ADP AEROPORTS DE PARIS SA
SOP SOPRA STERIA GROUP SA
ACN ACCENTURE PLC CLASS A
INF INFOTEL SA
SWP SWORD GROUP SE
AUB AUBAY SA
KER KERING SA
ATE ALTEN SA
CAP CAPGEMINI SE
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
HM B H&M HENNES & MAURITZ AB CLASS B
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
BP. BP P.L.C.
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
NA9 NAGARRO
DSY DASSAULT SYSTEMES SA
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
- Ghada Ben Sedrine
- Nicolas David
ADP AEROPORTS DE PARIS SA
SOP SOPRA STERIA GROUP SA
ACN ACCENTURE PLC CLASS A
INF INFOTEL SA
SWP SWORD GROUP SE
AUB AUBAY SA
KER KERING SA
ATE ALTEN SA
CAP CAPGEMINI SE
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
HM B H&M HENNES & MAURITZ AB CLASS B
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
BP. BP P.L.C.
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
NA9 NAGARRO
DSY DASSAULT SYSTEMES SA
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
- Nicolas David
- Nicolas Thorez
ACN ACCENTURE PLC CLASS A
INF INFOTEL SA
SWP SWORD GROUP SE
AUB AUBAY SA
ATE ALTEN SA
CAP CAPGEMINI SE
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
NA9 NAGARRO
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
- Nicolas David
- Nicolas Thorez
ACN ACCENTURE PLC CLASS A
INF INFOTEL SA
SWP SWORD GROUP SE
AUB AUBAY SA
ATE ALTEN SA
CAP CAPGEMINI SE
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
NA9 NAGARRO
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in I...
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific Evidence: The acceptance of 1 oral presentation, 5 digital oral presentations and 16 posters reflect an expanding dataset for obefazimod, including additional efficacy, safety, and cytokine data from the Phase 3 ABTE...
Abivax Presents Third Quarter 2025 Financial Results
Abivax Presents Third Quarter 2025 Financial Results Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 2027 PARIS, France, December 15, 2025, 10:05 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today its key financial info...
- Nicolas David
- Nicolas David
- Luis de Toledo Heras
- Luis de Toledo Heras
- Elias New
- Philip Hettich
GBT GUERBET SA
CDA COMPAGNIE DES ALPES SA
BOSS HUGO BOSS AG
A1XA4J CARBIOS SA
QDT QUADIENT SA
CAI CA IMMOBILIEN ANLAGEN AG
UBS UBM DEVELOPMENT AG
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
COPN COSMO PHARMACEUTICALS NV
M MED LIFE
WAVE WAVESTONE SA
LOUP SOCIETE L.D.C.
SHA SCHAEFFLER AG
- Elias New
- Philip Hettich
GBT GUERBET SA
CDA COMPAGNIE DES ALPES SA
BOSS HUGO BOSS AG
A1XA4J CARBIOS SA
QDT QUADIENT SA
CAI CA IMMOBILIEN ANLAGEN AG
UBS UBM DEVELOPMENT AG
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
COPN COSMO PHARMACEUTICALS NV
M MED LIFE
WAVE WAVESTONE SA
LOUP SOCIETE L.D.C.
SHA SCHAEFFLER AG
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.